Table 2.

Effect of SGLT2i in patients of NAFLD/NASH: Data from clinical studies.

SGLT2i	Types	Treatment duration	Population	Effects	Adverse events	References
Empaglifozin (10mg/day)	randomized, double-Blind, placebo-controlled Trial	24 weeks	NAFLD	improvement in liver steatosis and fibrosis	mild fungal vaginal infections and allergic reactions	Taheri et al. (70)
Empaglifozin (10mg/day)	randomized, double-Blind, phase 4, placebo-controlled Trial	24 weeks	T2DM with NAFLD	improvement in liver steatosis and fibrosis	no mention	Kahl et al. (76)
Ipragliflozin (50mg/day)	randomized, open-label, active-controlled trial (Pioglitazone 15-30 mg/day)	24 weeks	NAFLD	weight loss and abdominal fat area decrease	urinary tract infections, vaginal candidiasis	Ito et al. (78)
Ipragliflozin (50mg/day)	prospective study	24 weeks	T2DM with NAFLD/NASH	weight loss, improvement in liver enzymes, body fat mass and steatosis	no mention	Miyake et al. (79)
Ipragliflozin (50mg/day)	multicenter, open-label, randomized controlled trial	72 weeks	T2DM with NAFLD	improvement in liver fibrosis, blood sugar levels and obesity	frequent urination, increase in HbA1c	Takahashi et.al. (80)
Dapagliflozin (10mg/day) alone or combination of omega-3 (n-3) carboxylic acids (4g/day)	multicenter, double-blind, randomized, placebo-controlled trail	12 weeks	T2DM with NAFLD	biomarkers of liver cell injury decrease	mild or moderate in intensity	Eriksson et al. (82)
Dapagliflozin (5mg/day)	prospective, randomized, active-controlled, open-label trial	24 weeks	T2DM with NAFLD	improvement in liver steatosis and fibrosis	no mention	Shimizu et al. (83)
Dapagliflozin (5mg/day)	single center, double-blind, randomized, prospective study	12 weeks	NAFLD	weight loss, improvement in liver enzymes	NA	Tobita et al. (84)
Canagliflozin (100mg/day)	prospective, single center, single arm, nonrandomized, open, and uncontrolled clinical trial	24 weeks	T2DM with NAFLD	improvement in liver function and visceral fat	no mention	Akuta et al. (85)